Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Antibodies to Carbamylated Proteins Provide Insight into Rheumatoid Arthritis

By Labmedica International staff writers
Posted on 05 Feb 2013
Print article
Detection of antibodies to carbamylated proteins (anti-CarP) is an important advance in the diagnosis of Rheumatoid Arthritis (RA).

A study published in 2012 by a team at Leiden University Medical Center (LUMC; Leiden, The Netherlands) in Proceedings of the National Academy of Sciences of the United States of America (PNAS) showed that Immunoglobulin G (IgG) and IgA antibodies recognizing carbamylated antigens were present in about 50% of RA patients. Anti-CarP antibodies recognize homocitrulline and are therefore distinct from anticitrullinated protein antibodies (ACPA), including anti-cyclic citrullinated peptide (anti-CCP), a biomarker commonly used to diagnose RA. Anti-CarP IgG and IgA were detected in 16% and 30% of ACPA negative RA patients respectively. Additionally, anti-CarP antibodies were shown to be predictive of a more severe course of disease as measured by radiological progression in ACPA negative RA patients.

LUMC and Inova (San Diego, CA, USA) have announced the completion of an exclusive, worldwide license agreement for technology developed at LUMC to detect antibodies to carbamylated proteins (anti-CarP). "The detection of autoantibodies in sera of RA patients has provided important insight into the processes that initiate and drive RA. Since anti-CarP antibodies can also be detected in a subgroup of patients for whom so far no serological markers were available we believe this may provide new insight into the pathogenesis of RA,"said Dr. Leendert Trouw, assistant professor at LUMC.

Prof. Tom Huizinga, head of the department of Rheumatology at LUMC added "With new treatment options at hand it is now possible to apply early and aggressive treatment. Understanding which patients would benefit most from such an intervention is important to maximize efficiency, and detection of anti-CarP antibodies may identify such patients."

The LUMC is part of the Dutch Federation of University Medical Centers (NFU). The NFU is a collaboration of the eight University Medical Centers of The Netherlands.

Related Links:

Leiden University Medical Center
Inova



Print article

Channels

Genetic Tests

view channel

Patterns of MicroRNA Expression Distinguish Patients with Asthma and Allergic Rhinitis

Subsets of circulating micro RNAs (miRNAs) are uniquely expressed in asthmatic patients and in patients with allergic rhinitis (AR) and have potential for use as noninvasive biomarkers to diagnose and characterize these diseases. MicroRNAs are a class of about 20 nucleotides-long RNA fragments that block gene expression... Read more

Pathology

view channel

Liver Cancer May Be Diagnosed from Altered Sugar Metabolism

Altered gene expression that causes cancerous cells to metabolize fructose differently from healthy cells could be a significant new biomarker for diagnosing liver cancer. Dietary fructose is primarily metabolized in the liver and it has now been demonstrated that, compared with normal hepatocytes, hepatocellular carcinoma... Read more

Lab Tech.

view channel

Method Preserves Microfluidic Devices for HIV Monitoring in Developing Countries

Microfluidic devices with immunochemistry have broad applications in chemotherapy monitoring, transplant patient monitoring, and especially in monitoring the efficacy of antiretroviral therapy. Providing vital health care services to people in developing countries without reliable electricity, refrigeration and state-of-the-art... Read more

Industry News

view channel

R-Biopharm and Merck Partner on Companion Diagnostics

R-Biopharm AG (Darmstadt, Germany) and Merck KGaA (Darmstadt, Germany) have entered into an agreement that constitutes their first collaboration, which will initially focus on developing and launching companion diagnostics. Companion diagnostics play a central role in personalized medicine by helping to find specific... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.